Trial Profile

An Open Label, Randomized, Phase 1/2 Trial Of The Safety, Tolerability, And Immunogenicity Of Meningococcal Group B Rlp2086 Vaccine In Healthy Infants.

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Meningococcal vaccine group B (Primary)
Indications Meningococcal group B infections
Focus Adverse reactions; Pharmacodynamics
Sponsors Pfizer

Most Recent Events

27 Jun 2012 Planned number of patients changed from 376 to 744 as reported by EudraCT.
29 Apr 2011 Status changed from not yet recruiting to discontinued.
07 Jul 2010 Planned initiation date changed from 1 Nov 2009 to 1 Feb 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com